WALTHAM, Mass. — Vicarious Surgical Inc. (OTCID: RBOT), a robotics technology company developing a next-generation platform for minimally invasive surgery, announced a series of strategic actions aimed at strengthening its financial position, improving trading liquidity, and supporting a potential relisting of its common stock on a national exchange.
The company said it has implemented operational and cost-discipline measures in recent months to align expenses with its current development stage while maintaining progress toward key technology milestones.
As a result of these efforts, Vicarious Surgical expects its full-year 2026 cash burn to be approximately $19 million, down from about $35 million projected in guidance issued in late 2025. In mid-2025, the company’s annual cash burn had been roughly $50 million.
The reduction reflects structural changes to the company’s cost profile, including increased use of outsourcing and operational efficiencies, while maintaining progress toward development goals.
Despite the cost reductions, the company said development of the Vicarious Surgical System remains on schedule. The company is targeting a system design freeze by the end of 2026, a key milestone in its regulatory and commercialization roadmap.
Based on its current operating plan, the company believes its existing cash resources will provide runway through the second quarter of 2026 as it pursues its capital markets strategy.
As part of that strategy, Vicarious Surgical has submitted an application to list its Class A common stock on the Nasdaq Capital Market.
The company has also filed a preliminary proxy statement with the U.S. Securities and Exchange Commission seeking shareholder approval to allow its board of directors to implement a reverse stock split of its common stock at a ratio to be determined by the board. The move is intended to help the company meet Nasdaq’s minimum bid price requirement for listing.
Vicarious Surgical said it is also evaluating capital-raising options to support continued development of the Vicarious Surgical System and help meet Nasdaq’s initial listing requirements. The company cautioned that there is no assurance it will be able to satisfy Nasdaq’s listing standards or complete any proposed financing.
After recently transitioning from the New York Stock Exchange, the company’s shares began trading on the OTCID market tier. Vicarious Surgical said it has applied to upgrade its quotation to the OTCQB Venture Market, which serves early-stage and developing companies.
The company said trading on the OTCQB Venture Market could increase market visibility and encourage greater participation from market makers, potentially improving trading liquidity while it pursues a relisting on a national exchange.
“Over the past several months, we have taken decisive steps to streamline our operating structure and significantly reduce our cash burn while maintaining our core development timeline,” said Stephen From, Chief Executive Officer of Vicarious Surgical.
“These actions position us with a more capital-efficient operating model while we continue advancing toward system design freeze by year-end. At the same time, we are actively pursuing a path back to a national exchange through our Nasdaq listing application. We believe these steps strengthen our foundation and support our long-term objective of bringing our robotic surgical platform to market.”
